News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Data Regarding Transfusion-Related Reactions For Fenwal Intersolâ„¢ Solution



3/24/2014 9:46:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fenwal, a Fresenius Kabi company, announced today it is has received FDA clearance to include new clinical data in the product label of its platelet additive solution, InterSolâ„¢ (PAS 3). A multi-center, non-randomized, open-label retrospective medical chart review study involving about 14,000 transfusions looked at adverse events related to platelet transfusion with and without additive solution. Platelet transfusions using Fenwal InterSol led to a 0.55 percent adverse event reaction rate, while transfusions using only plasma platelets led to a 1.37 percent adverse event reaction rate.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Fenwal
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES